Logan Lutton

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its impact depends on access, patient-centered care and affordability.

Integrating HIV and sexual health care is essential for improving outcomes, but global stigma, funding cuts—especially the defunding of USAID—and structural barriers like limited access and political resistance continue to hinder progress, experts emphasized at IAS 2025.

There is currently a movement to “de-medicalize" PrEP by pushing for more availability at more casual settings than government clinics, according to Anna Bershteyn, Ph.D., associate professor in the Department of Population Health, NYU Grossman School of Medicine.

The most common HIV antibody blood test is called an “A-0” test, which is available for approximately 70 cents in many low- and middle-income countries, according to Anna Bershteyn, Ph.D., associate professor in the Department of Population Health, NYU Grossman School of Medicine.

Here’s what you missed this week on Managed Healthcare Executive.

A new survey by eHealth and Retirable finds that 80% of Americans worry Medicare and Social Security won’t be available when they need them, amid projections that both trust funds could be depleted by 2034.

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, according to the Merck news release.

Period-induced alcohol cravings and societal changes are contributing to a rising trend in women drinking, according to new research from Sarah McKetta, M.D., Ph.D., assistant professor, Mailman School of Public Health, Columbia University and Layne Robinson, clinical psychology doctoral student and graduate research assistant in the RISK Laboratory, University of Kentucky.

Menopause therapy coverage varies by insurance type and is dependent on FDA approval status, clinical guidelines and prior authorizations, all of which are best navigated with the help of a managed care pharmacy expert, according to Susan Cantrell, CEO, Academy of Managed Care Pharmacy.

The prevalence of autoimmune disease patients with a mental health disorder is almost twice the number of patients without, suggesting there is a link between inflammation and conditions such as depression, anxiety disorder and bipolar disorder.

Orsini will be the specialty pharmacy partner for Ekterly.

Here’s what you missed this week on Managed Healthcare Executive.

While the impact of Medicaid changes on employer-sponsored insurance remains to be seen, competition between providers is a steadfast way to stabilize the system for everyone, according to Christoph Dankert, chief network officer of Carrum Health.

Care gaps in women’s health are closing, thanks to increased cultural awareness of gendered healthcare disparities, according to Susan Cantrell, CEO of the Academy of Managed Care Pharmacy.

Sonali Kulkarni, M.D., M.P.H., Medical Director in the Division of HIV and STD Programs at the Los Angeles County Department of Public Health, recently sat down with Managed Healthcare Executive to explain the barriers within the traditional healthcare system for homeless HIV patients and the importance of mobile care clinics.

The financial balancing act between providers, government programs and commercial insurers, according to Christoph Dankert, chief network officer of Carrum Health.

Patients addicted to opioids receive less mental health care if they are only covered by public insurance, compared with patients receiving care through alternate funding, according to a recent study published in Addiction Science & Clinical Practice.

Here’s what you missed this week on Managed Healthcare Executive.

Employers are key to transforming healthcare by creating competitive, cost-effective networks independent of federal policy changes, according to Christoph Dankert, chief network officer of Carrum Health.

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their prescription filled through CenterWell Pharmacy, now associated with Novo Nordisk and WeightWatchers.

This latest data is a change from previous survey answers, in which 71% of healthcare leaders expected improved profitability and 69% of leaders anticipated a rise in revenue in 2025, according to combined data from the Deloitte Center for Health Solutions.

The letter, signed by 79 medical societies, expresses concern over recent federal immunization review policies and asks that vaccines remain available to patients without cost-sharing.

There are a variety of reasons for this, including stigma, substance use disorders and trauma, according to Sonali Kulkarni, medical director in the Division of HIV and STD Programs at the Los Angeles County Department of Public Health.

Women primary care providers (PCPs) treating Medicare patients in a value-based care model achieved better patient outcomes and earned more per patient than male counterparts, despite receiving equal patient satisfaction ratings, highlighting a potential for value-based payment to help close the gender pay gap.

Ways health systems can support care teams treating postpartum hemorrhage and the potential impacts of the Trump administration’s diversity, equity and inclusion (DEI) policies, according to Abigail Wooldridge, assistant professor of Industrial and Enterprise Systems Engineering at the University of Illinois.

Here’s what you missed this week on Managed Healthcare Executive.

Extreme weather leads to autoimmune disease flare-ups, which can cause a loss of refrigerated medication, according to the results of recent research from the Autoimmune Association.

An experienced team of healthcare providers used to working together will likely be more successful when treating a postpartum hemorrhage, according to Abigail Wooldridge, assistant professor of Industrial and Enterprise Systems Engineering at The University of Illinois.

This is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) and the second indication for Monjuvi.